Literature DB >> 7767785

Rat epidermal cathepsin B: purification and characterization of proteolytic properties toward filaggrin and synthetic substrates.

A Kawada1, K Hara, K Morimoto, M Hiruma, A Ishibashi.   

Abstract

The aim of this study was to purify epidermal cathepsin B from rat skin and investigate its proteolytic activities on filaggrin and several synthetic substrates. The molecular weight of purified monomeric cathepsin B was estimated to be 30 kDa by SDS-polyacrylamide gel electrophoresis. The amino acid composition, similar to that of liver cathepsin B, indicated the enzyme to be an acidic protease. The enzyme had strong hydrolytic activity toward N-benzyloxy-carbonyl-L-arginyl-L-arginine-7-amido-4-methylcoumarin (Z-Arg-Arg-MCA) (152 mU/mg) and N-benzyloxycarbonyl-L-phenylalanyl-L-arginine-7-amido-4-methylcoumarin (424 mU/mg), but had no proteolytic activity toward L-arginine-7-amido-4-methylcoumarin. The Km value for Z-Arg-Arg MCA was 0.34 mM and pH optimum was 5.5. Cathepsin B degraded rat epidermal filaggrin into small fragments at pH 4.0 and 5.5., and was inhibited by a specific cysteine proteinase inhibitor, N-[N-(L-3-trans-carboxyoxirane-2-carbonyl)L-leucyl]- agmatin. This study demonstrated that filaggrin was susceptible to degradation by cathepsin B. Such an action may have relevance to skin differentiation in which acid proteases are thought to participate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767785     DOI: 10.1016/1357-2725(94)00072-j

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  1 in total

1.  A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis.

Authors:  Aishath S Naeem; Cristina Tommasi; Christian Cole; Stuart J Brown; Yanan Zhu; Benjamin Way; Saffron A G Willis Owen; Miriam Moffatt; William O Cookson; John I Harper; Wei-Li Di; Sara J Brown; Thomas Reinheckel; Ryan F L O'Shaughnessy
Journal:  J Allergy Clin Immunol       Date:  2016-11-29       Impact factor: 10.793

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.